FORT COLLINS — Ventria Bioscience is making a drug that CEO Scott Deeter hopes someday will generate several billion dollars in revenue.

There are, of course, a few hurdles first.

Ventria has developed a method to make proteins and store them in self-pollinating plants such as rice and barley. The company plans to use those proteins, developed affordably and on a large scale, in drugs for worldwide distribution.

“Many of the biotech medicines are not available on a global basis,” said Deeter, who was recently named a board member of the Colorado BioScience Association. “It’s really our vision to make biotech medicine more available on a global basis because of this technology.”

Established in 2001, the privately held drug company’s laboratories are located in the Rocky Mountain Innosphere in Fort Collins. Ventria maintains exclusive rights to more than 25 issued patents and is in the process of securing another 21 patents.

“They’re special because the material they use is plant-based, which is different from other companies that provide proteins for commercialization,” said Holli Riebel, president and CEO of the bioscience